In HNSCC, CD147 promotes tumor progression through activation of the nuclear factor-κB (NF-κB) signaling pathway (53) and enhances resistance to chemotherapeutic agents via the MAPK/ERK cascade (54). Here, NFKB1 is linked to head and neck squamous cell carcinoma.